A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study

被引：15
|
作者：
Sotiriou, E. [1 ]
Bakirtzi, K. [1 ]
Papadimitriou, I. [1 ]
Tsentemeidou, A. [1 ]
Eftychidou, P. [1 ]
Eleftheriadis, V. [1 ]
Lallas, A. [1 ]
Ioannides, D. [1 ]
Vakirlis, E. [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Dermatol & Venereol 1, Thessaloniki, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 05期
关键词：
D O I：
10.1111/jdv.17880
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E359 / E361
页数：3
相关论文
共 50 条
  • [1] Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience
    Calianno, Gianluca
    Esposito, Maria
    Fidanza, Rosaria
    Palmieri, Maria
    Fargnoli, Maria Concetta
    [J]. DERMATOLOGIC THERAPY, 2021, 34 (04)
  • [2] Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
    Gonulal, Melis
    Balci, Didem Didar
    Ozturkcan, Serap
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3653 - 3659
  • [3] Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 1028 - 1030
  • [4] A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial
    Blauvelt, A.
    Leonardi, C.
    Elewski, B.
    Crowley, J. J.
    Guenther, L. C.
    Gooderham, M.
    Langley, R. G.
    Vender, R.
    Pinter, A.
    Griffiths, C. E. M.
    Tada, Y.
    Elmaraghy, H.
    Lima, R. G.
    Gallo, G.
    Renda, L.
    Burge, R.
    Park, S. Y.
    Zhu, B.
    Papp, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (06) : 1047 - 1058
  • [5] Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study
    Hagino, Teppei
    Onda, Marina
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. JOURNAL OF DERMATOLOGY, 2024,
  • [6] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
    Mease, Philip J.
    Smolen, Josef S.
    Behrens, Frank
    Nash, Peter
    Leage, Soyi Liu
    Li, Lingnan
    Tahir, Hasan
    Gooderham, Melinda
    Krishnan, Eswar
    Liu-Seifert, Hong
    Emery, Paul
    Pillai, Sreekumar G.
    Helliwell, Philip S.
    Naftal, Leonardo
    Hidalgo, Rodolfo Ariel Pardo
    Kerzberg, Eduardo Mario
    Savio, Veronica Gabriela
    Lazaro, Alicia
    Velasco, Benito Jorge
    Verzero, Norma Beatriz
    Asnal, Cecilia Adma
    Mysler, Eduardo Fabian
    Berman, Alberto
    Ariel, Federico Javier
    Rischmueller, Maureen
    Zochling, Jane Margaret
    Bird, Paul A.
    Hall, Stephen
    Ostor, Andrew
    Romas, Evange
    Stummvoll, Georg
    Machold, Klaus
    Spellitz, Peter
    Hanusch, Ursula
    Vanden Berghe, Marc
    Leon, Marc
    Vanhoof, Johan Louis Magda
    Van den Bosch, Filip Eduard Jeanne
    De Vlam, Kurt Leo Francois
    Morin, Frederic
    Bessette, Louis
    Haaland, Derek A.
    Schlemmer, Annette Margrethe
    Kristensen, Lars Erik
    Jarvinen, Pentti
    Peltomaa, Ritva Liisa
    Pirila, Laura
    Vuotila, Jorma
    Lespessailles, Eric
    Goupille, Philippe
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 123 - 131
  • [7] One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study
    Magdaleno-Tapial, Jorge
    Ortiz-Salvador, Jose Maria
    Santos-Alarcon, Sergio
    Belinchon-Romero, Isabel
    Sahuquillo-Torralba, Antonio
    Gonzalez-Delgado, Victor
    Sabater-Abad, Javier
    Armengot-Carbo, Miquel
    Mari-Ruiz, Juan Ignacio
    Mateu-Puchades, Almudena
    Mataix-Diaz, Javier
    Schneller-Pavelescu, Luca
    Carmena-Ramon, Rafael
    Martorell, Antonio
    Sanchez-Carazo, Jose Luis
    [J]. DERMATOLOGIC THERAPY, 2024, 2024
  • [8] Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study
    Hagino, Teppei
    Onda, Marina
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024,
  • [9] A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis
    Hansel, K.
    Zangrilli, A.
    Bianchi, L.
    Peris, K.
    Chiricozzi, A.
    Offidani, A.
    Diotallevi, F.
    Fargnoli, M. C.
    Esposito, M.
    Amerio, P.
    Gualdi, G.
    Bianchi, L.
    Stingeni, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (02) : E111 - E113
  • [10] Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
    Caldarola, Giacomo
    Zangrilli, Arianna
    Palmisano, Gerardo
    Bavetta, Mauro
    Moretta, Gaia
    Pagnanelli, Gianluca
    Panasiti, Vincenzo
    Bianchi, Luca
    De Simone, Clara
    Peris, Ketty
    [J]. DRUGS IN CONTEXT, 2023, 12
12345